Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening Products

Washington D.C., Makes Improvements On HIV/AIDS Efforts, But More Work To Be Done, Report Finds; District Expands STD Testing Program For Students
The fifth annual report card from the Washington, D.C.,-based Appleseed Center for Law and Justice examining the district"s response to HIV gives the city "high marks for rapid testing, interagency coordination, surveillance and fighting the disease in the D.C. Jail," but finds that the city falls short in other areas, the Washington Examiner reports (Neibauer, 8/5). "The government also received above-average grades for leadership, managing grants to groups that help people with the illness, and monitoring the effectiveness of those programs," the Washington Post reports. However, "While Mayor Fenty and his administration deserve recognition for the continued support of ò€¦ numerous [HIV/AIDS Administration] initiatives, his public appearances and statements about the epidemic have fallen short of his enthusiasm for action inside the government," the report said. The report added that the district could do more to address HIV and recommended that HAA assess whether the improvements they have made are reducing the spread of the virus, according to the Post (Fears, 8/5).
generic viagra online
New Study Shows That Next Generation FlexPen(R) Has A Significantly Lower Injection Force Than SoloStar(R) And KwikPen(R)
New data published this week in Expert Opinion Pharmacotherapy has revealed that Next Generation FlexPen®, Novo Nordisk"s prefilled insulin delivery device, has a significantly lower injection force than two other devices, SoloStar® and KwikPen®.(1,2,3) Previous studies show that people with diabetes prefer a lower injection force.(4,5)
News of the day
New Studies Show Nursing Workforce Critical To Success Of Health Reform
Health Affairs unveiled a series of six studies examining the nursing workforce in the context of health reform. The papers were released at a forum presented by Health Affairs and the Center to Champion Nursing in America (CCNA) that featured a lively discussion among policy-makers, nursing leaders and researchers, and health reform experts. The Center is a joint initiative of AARP, the AARP Foundation and the Robert Wood Johnson Foundation.
Cardiovascular

CytRx Drug Candidate INNO-206 Results In Ovarian Tumor Shrinkage In Animal Trials

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, announced that results demonstrating that its cancer drug candidate INNO-206 caused statistically significant tumor shrinkage in an animal model of ovarian cancer have been accepted for publication in the peer-reviewed journal Investigational New Drugs. The manuscript based on this animal trial, "INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model," was made available ahead of journal printing in electronic format in the January 8, 2009 on-line issue of Investigational New Drugs. "Ovarian cancer ranks ninth in prevalence and fifth in mortality among cancers in American women, making it a major women"s healthcare concern," said Steven A. Kriegsman, CytRx President and CEO. "Data from this highly promising animal trial showed actual shrinkage of ovarian cancer tumors following treatment with INNO-206 and further add to accumulating evidence that INNO-206 has therapeutic potential in multiple cancer forms." CytRx has the exclusive worldwide rights to INNO-206, which holds the potential as an effective treatment in a variety of cancer indications, including sarcomas, breast cancer, pancreatic cancer and non-Hodgkin"s lymphoma. INNO-206 is a pro-drug derivative of doxorubicin, itself an effective and often prescribed chemotherapeutic drug. INNO-206 is designed to reduce adverse events by controlling drug release and to increase efficacy by preferentially targeting tumors throughout the body, allowing accumulation of the toxic drug at the tumor site. In a Phase 1 study, INNO-206 was administered at up to six times the standard dosing of doxorubicin without an increase in observed side effects compared to those historically seen with doxorubicin. In the animal study, conducted under the direction of INNO-206 inventor Felix Kratz, Ph.D., Department of Medical Oncology, Clinical Research, at the Tumor Biology Center in Freiburg, Germany, 10 million human A2780 ovarian tumor cells from cell culture were transplanted under the skin in the left flank region of 18 mice with immune systems compromised to allow tumor cell growth. After 10 days, the tumors reached a palpable size and the experimental animals were then randomized into three groups for administration of two cycles of weekly intravenous injections with a previously optimized dose of doxorubicin or CytRx"s INNO-206, or received an intravenous injection lacking either drug to serve as a control. Tumor growth was monitored continuously for 12 days following initiation of treatment. ò€¢ In the control group, tumors grew rapidly, increasing in average volume by approximately 20-fold. ò€¢ A statistically significant decrease in the rate of tumor growth compared to the control was observed in the doxorubicin treated group, with tumors increasing in volume by only four- to five-fold during treatment. ò€¢ By contrast to the other two groups of animals, the average tumor growth in animals treated with INNO-206 was completely inhibited, and in fact these tumors shrank in volume, resulting in a net two- to three-fold decrease in tumor volume during treatment. The decrease in average tumor volume in animals treated with INNO-206 was statistically significant (pAbout Ovarian Cancer According to the American Cancer Society (ACS), ovarian cancer is the ninth most prevalent form of cancer but the fifth most common cause of cancer mortality in women in the U.S. with a 45% five-year survival rate. In 2009, approximately 22,000 new cases and almost 15,000 deaths are expected from ovarian cancer in the U.S. alone. The ACS estimates that one out of 71 women will develop ovarian cancer sometime in their life. About INNO-206 INNO-206 is a prodrug of the commonly prescribed chemotherapeutic doxorubicin and was designed to reduce adverse events by controlling release and preferentially targeting the tumor. In a Phase 1 study, doses were administered at up to six times the standard dosing of doxorubicin without an increase in observed side effects over those historically seen with doxorubicin. The Company is evaluating options for a possible Phase 2 clinical trial. CytRx Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009